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dbstract
We investigated the peripheral blood gene expression profile of interferon induced transmembrane protein 1 (IFITM1) in sixty chronic
yeloid leukemia (CML) patients classified according to new prognostic score (NPS). IFITM1 is a component of a multimeric complex
nvolved in the trunsduction of antiproliferative and cell adhesion signals. Expression level of IFITM1 was found significantly different
etween the high- and low-risk groups (P = 9.7976 × 10−11) by real-time reverse transcription polymerase chain reaction (RT-PCR). Higher
FITM1 expression correlated with improved survival (P = 0.01). These results indicate that IFITM1 expression profiling could be used for
olecular classification of CML, which may also predict survival.
2004 Elsevier Ltd. All rights reserved.
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. Introduction
Chronic myeloid leukemia (CML) patients can be divided
nto three groups of low-risk, intermediate-risk, and high-
isk, based on clinical parameters known as NPS [1]. Re-
ponse of these risk groups to treatment is not uniform [2,3].
or example, low-risk patients respond better to interferon-.
lthough CML was the first human disease in which a spe-
ific chromosomal abnormality [t(9; 22) (q34; q11)] could
e linked to the pathogenic events of leukemogenesis [4,5],
he gene expression profiles associated with each risk group
emain unknown.
∗ Corresponding author. Tel.: +90 312 290 2139; fax: +90 312 266 5097.
E-mail address: tozcelik@fen.bilkent.edu.tr (T. ¨Ozc¸elik).
IFITM1, a component of a multimeric complex involved
in the trunsduction of antiproliferative and cell adhesion sig-
nals [6], was suggested to play a role in the antiproliferative
activity of interferons [7]. The sensitivity to inhibition of cell
growth induced by interferons was found to correlate with the
expression of this gene in various cell lines [8–10]. Further-
more, culture of human RSa cells with interferon- resulted
in increased resistance of the cells to cell killing by X-rays,
and increased levels of IFITM1 mRNA [11].
We hypothesized that IFITM1 could be a molecular marker
to identify patients in different CML risk groups based on
the observations that this gene has a role in the antiprolifer-
ative activity of interferons, and low-risk CML patients re-
spond better to interferon- treatment. Therefore, we col-
lected blood samples from 60 consecutive CML patients
145-2126/$ – see front matter © 2004 Elsevier Ltd. All rights reserved.
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classified according to NPS at initial diagnosis, analyzed
IFITM1 expression levels by real-time reverse transcription
polymerase chain reaction (RT-PCR), and performed Kaplan-
Meier analysis to correlate survival with IFITM1 expression.
2. Materials and methods
2.1. Patients
Blood was obtained from high-risk (n = 16, NPS:
1484→3853), intermediate-risk (n = 11, NPS:784→1379),
and low-risk (n = 33, NPS:21→708) CML patients, as well
as four apparently healthy volunteers, following written in-
formed consent. Patients ranged in age from 20 to 80 years
old, with a mean age of 43.4 ± 13.2 (mean ± S.D.), and
a male to female ratio of 28–32 (Table 1). CML diagnosis
was confirmed in all patients by in situ hybridization (Vy-
sis Inc.) and by RT-PCR (Roche, Molecular Biochemicals)
for BCR-ABL fusion. Regardless of risk group assignment,
all patients received a short course of hydroxyurea followed
by hydroxyurea or interferon during the median follow up
duration of 26.5 months. Six patients who did not achieve re-
mission with interferon based on BCR-ABL fusion analysis,
received imatinib mesilate sequentially. Four patients (two
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Table 1
Patient characteristics
Risk group/patient no. Sex Age NPS Disease phase
High (n = 16)
CML-3 F 45 1511 Blastic
CML-7 F 22 3853 Blastic
CML-32 F 38 2550 Blastic
CML-45 M 56 1513 Blastic
CML-4 M 42 1968 Accelerated
CML-2 M 31 1495 Chronic
CML-10 F 50 1783 Chronic
CML-15 F 29 1484 Chronic
CML-23 M 28 1672 Chronic
CML-55 M 53 1604 Chronic
CML-58 F 52 1514 Chronic
CML-64 F 20 1518 Chronic
CML-71 M 50 1496 Chronic
CML-87 F 51 1511 Chronic
CML-89 M 55 1617 Chronic
CML-91 M 37 1498 Chronic
Low (n = 33)
CML-6 M 24 142 Chronic
CML-8 M 35 584 Chronic
CML-12 F 52 708 Chronic
CML-13 M 40 578 Chronic
CML-14 F 46 383 Chronic
CML-17 M 63 708 Chronic
CML-18 F 25 41 Chronic
CML-22 M 36 635 Chronic
CML-25 F 43 259 Chronic
CML-29 M 36 259 Chronic
CML-31 F 47 21 Chronic
CML-46 F 39 21 Chronic
CML-51 F 38 25 Chronic
CML-54 F 42 141 Chronic
CML-56 M 46 112 Chronic
CML-59 F 32 204 Chronic
CML-60 F 65 667 Chronic
CML-62 M 35 497 Chronic
CML-65 F 47 204 Chronic
CML-68 F 37 210 Chronic
CML-69 M 24 550 Chronic
CML-70 F 58 667 Chronic
CML-74 F 23 141 Chronic
CML-75 F 34 214 Chronic
CML-78 M 49 164 Chronic
CML-79 F 26 21 Chronic
CML-80 F 33 42 Chronic
CML-81 M 38 217 Chronic
CML-82 F 25 105 Chronic
CML-83 M 51 708 Chronic
CML-84 F 43 576 Chronic
CML-85 F 47 259 Chronic
CML-86 M 29 284 Chronic
Intermediate (n = 11)
CML-38 M 54 784 Blastic
CML-63 M 69 1017 Accelerated
CML-9 M 43 830 Chronic
CML-11 M 70 1025 Chronic
CML-19 F 51 1238 Chronic
CML-20 F 51 1310 Chronic
CML-28 M 57 1169 Chronic
CML-30 F 66 1379 Chronic
CML-43 M 42 1102 Chronicow, one intermediate and one high-risk) received stem cell
ransplantation from siblings and are still alive.
.2. RNA isolation
For gene expression analysis in CML it is important to in-
lude all types of leukocytes since CML involves cells from
ultiple heamatopoietic lineages [4]. Therefore, RNA was
solated from the buffy coat. Consequently, our results rep-
esent gene expression from whole blood leukocytes. Total
NA was extracted with trizol (Invitrogen) and treated with
NaseI (DNA-free, Ambion) according to manufacturer’s in-
tructions [12]. Concentration and purity of the total RNAs
ere determined on the Beckman spectrophotometer Du640
Beckman Instruments Inc.). All samples were run on dena-
uring agarose gel.
.3. Real-time quantitative RT-PCR
The real-time RT-PCR assays were done with the iCy-
ler instrument (BioRad Laboratories) using lightcycler-
NA master SYBR Green I (Roche, Molecular Bio-
hemicals). The sequence of the primers used were:
FITM1 F-5′-TGCACAAGG AGGAACATGAG-3′; IFITM1
-5′-CTGTTACAGAGCCGAATACC-3′. GAPDH was used
s internal control (F-5′-GGCTGAGAACGGGAAGCTTG-
CAT-3′ and R-5′-CAGCCTTCTCCATGGTGGTGAAGA-
′
. Equal amounts of total RNA (3g for each sample) were
sed in cDNA synthesis (RevertAid First Strand cDNA syn-
hesis kit, MBI-Fermentas), and the quality of cDNA was ini-
ially tested by GAPDH RT-PCR amplification using 1/40 v
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Table 1 (Continued )
Risk group/patient no. Sex Age NPS Disease phase
CML-72 F 80 912 Chronic
CML-73 M 53 1080 Chronic
F: female; M: male; NPS: new prognostic score.
of cDNA. A pool of RNA from leukocytes of four healthy vol-
unteers was used as control sample. The PCR reactions were
set up in a volume of 20l, containing 5l of sample cDNA
(1:5 dilution of the RT reaction in nuclease free water), 1 ×
SYBR Green I dye, 1.5 mM MgCl2, and 5 pmol from IFITM1
and GAPDH specific primers. The cycling conditions were
as follows: 95 ◦C for 30 s, 55 ◦C for 30 s, and 72 ◦C for 30 s
for 45 cycles with initial melting at 95 ◦C for 5 min.
Relative expression levels were calculated using the PCR
threshold cycle number (CT) for each CML and control sam-
ple (both of which were normalized according to GAPDH
mRNA for differences in amount of total RNA added to
the reaction), using the formula 2−(CTsample−CTcontrol)
[13–15].CT represents the difference inCT values between
the target andGAPDH transcripts. RT-PCR was performed in
duplicates for each sample and averageCT values were calcu-
lated. Levels of gene transcripts between high- and low-risk
CML were compared using Mann–Whitney U-test (Matlab
6 www.mathworks.com mannwhit matlab routine, http://
www.biol.ttu.edu/Strauss/Matlab/matlab.htm) [16].P-values
<0.05 were considered statistically significant differences.
3. Results
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Fig. 1. Relative expression of IFITM1 by real-time RT-PCR in CML risk
groups. Levels of gene transcripts between high- and low-risk CML were
compared and found to be highly significant (P = 9.7976 × 10−11).
Fig. 2. Kaplan–Meier analysis: Kaplan–Meier plot of overall survival of
patients according to IFITM1 (P = 0.01) expression.
4. Discussion
Although gene expression profiles associated with CML
have been reported [17,18], to the best of our knowledge,
this is the first study in which IFITM1 transcript levels at
initial diagnosis are correlated with clinical parameters and
survival. Currently, in the era of molecularly targeted thera-
pies, use of interferon- has been widely replaced by imatinib
mesilate treatment. However, there are patients who do not
respond to imatinib mesilate or develop resistance to it. These
patients could be candidates for interferon administration or
other treatment modalities. Thus a predictive test, which en-
ables clinicians to select the most suitable treatment agent,.1. Real-time RT-PCR results
We determined the relative transcript level of IFITM1 in
0 CML patients by real-time RT-PCR analysis. The results
howed that the relative transcript levels were significantly
ifferent between the high-risk (ranged between 0.0014 and
.67; n = 16), and low-risk (1.2–6.1; n = 33) groups (P =
.7976 × 10−11). The intermediate-risk group (0.8–5.2; n =
1) was similar to the low-risk group. The relative expression
f IFITM1 in different CML risk groups is shown in Fig. 1.
.2. Kaplan–Meier analysis
We performed Kaplan–Meier analysis in all patients who
ave follow-up data for at least 26.5 months (n = 24). When
atient survival was plotted according to IFITM1 expression,
ndependently of risk group assignment below or above the
utoff value of 1.0, the low-risk patients demonstrate higher
evels of IFITM1 expression compared to the high-risk pa-
ients. This finding significantly correlates with survival (P =
.01; Fig. 2). Use of treatment drugs, hydroxyurea or inter-
eron, were similar in all risk groups. Among the nine patients
ith the lowest IFITM1 levels (<0.5), response to interferon
as available in only two: both patients were resistant to in-
erferon and imatinib mesilate.
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would be dramatically useful. Our results shows that the ex-
pression level of IFITM1 is significantly different between
the high- and low-risk groups (P = 9.7976 × 10−11), and
higher IFITM1 expression correlates with improved survival
(P = 0.01). For example, high-risk CML patients who are ex-
pected to have a high proliferative capacity display decreased
IFITM1 expression. In an earlier study that was conducted by
our group, IFITM1 was found to be a differentially expressed
transcript between two high-risk and two low-risk patients an-
alyzed by cDNA microarrays [19]. Our results are also consis-
tent with the previous observation that reports IFITM1 in the
control of cell growth by its antiproliferative activity [6]. In-
terestingly, interferon induced protein with tetratricopeptide
repeats-2 (IFIT2) was found to be the most highly expressed
gene during the chronic phase of CML [17]. These results
suggest that higher expression of interferon induced genes in
CML patients may serve as indicators of interferon- sen-
sitivity, which in turn may be used as molecular markers to
predict response to interferon- treatment.
IFITM1 expression levels do not appear to be directly cor-
related with the blast counts of the patients based on the real-
time RT-PCR results. For example, the highest blast counts
in low-risk patients were within a range of 5–8%, yet their
IFITM1 expression levels were higher than all of the high-risk
patients including those with the lowest blast counts (4–8%).
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